Department of Respiratory Diseases, Children's Hospital affiliated to Shandong University, Jinan, China.
Jinan Key Lab of Respiratory Diseases for Children, Jinan Children's Hospital, Jinan, China.
Immun Inflamm Dis. 2023 Jul;11(7):e922. doi: 10.1002/iid3.922.
The global spread of coronavirus disease 2019 (COVID-19) has resulted in a significant disease burden, yet asthma patients do not have the expected high morbidity and mortality rates in the pandemics of COVID-19.
To find the difference of angiotensin-converting enzyme 2 (ACE2) in asthma and nonasthma children and evaluate the effect of inhaled corticosteroids (ICS) on its expression.
The ACE2, immunoglobulin E (IgE), and eosinophils were tested in different children.
A total of 157 children aged 3-16 years were enrolled. The expression of ACE2 in asthma children were lower than nonasthma children (T = -2.512, p = .013). Allergic nonasthma children had a significant higher ACE2 expression than children with allergic asthma (p = .013) and nonallergic asthma (p = .029). The expression of ACE2 had no significant difference between first-diagnosed asthma children and that had been treated with ICS for ≥6 months (F = 0.028, p = .598). The allergic asthma children showed a significantly higher eosinophils cells (EC) count than the allergic nonasthma (W = 200, p < .001) and nonallergic nonasthma children (W = 1089, p < .001). Nonallergic asthma children also had a significant higher EC count than the allergic non-asthma (W = 182.5, p < .001) and nonallergic non-asthma (W = 200.5, p < .001) children. There was no significant difference in IgE levels between asthmatic children and non-asthmatic children (W = 2792.5, p = .18).
Circulating ACE2 levels in asthmatic children were lower than those in non-asthmatic children and ICS treatment for ≥6 months did not affect the expression of ACE2 in peripheral blood in the asthma children.
2019 年冠状病毒病（COVID-19）的全球传播导致了重大的疾病负担，但哮喘患者在 COVID-19 大流行中的发病率和死亡率并未如预期的那样高。
寻找哮喘和非哮喘儿童之间血管紧张素转换酶 2（ACE2）的差异，并评估吸入皮质类固醇（ICS）对其表达的影响。
在不同的儿童中测试 ACE2、免疫球蛋白 E（IgE）和嗜酸性粒细胞。
共纳入 157 名 3-16 岁儿童。哮喘儿童的 ACE2 表达低于非哮喘儿童（T=-2.512，p=.013）。过敏性非哮喘儿童的 ACE2 表达显著高于过敏性哮喘儿童（p=.013）和非过敏性哮喘儿童（p=.029）。初诊哮喘儿童与接受 ICS 治疗≥6 个月的哮喘儿童之间 ACE2 的表达无显著差异（F=0.028，p=.598）。过敏性哮喘儿童的嗜酸性粒细胞（EC）计数明显高于过敏性非哮喘儿童（W=200，p<.001）和非过敏性非哮喘儿童（W=1089，p<.001）。非过敏性哮喘儿童的 EC 计数也明显高于过敏性非哮喘儿童（W=182.5，p<.001）和非过敏性非哮喘儿童（W=200.5，p<.001）。哮喘儿童和非哮喘儿童的 IgE 水平无显著差异（W=2792.5，p=.18）。
哮喘儿童外周血循环 ACE2 水平低于非哮喘儿童，ICS 治疗≥6 个月不影响哮喘儿童外周血 ACE2 的表达。
